Shots:

• The new analyses of the P-III BREEZE-AD5 trial and an extended safety analysis across multiple trials for Olumiant (2mg- qd) vs PBO in patients with AD showed improvements in the severity and extent of AD and patient outcomes- other key symptoms- and QoL as early as 1wks.
• Olumiant has also evaluated in patients with BSA >50% at baseline showed improvements in the severity and extent of AD and achieved 75% improvement in EASI 75. Safety was consistent with the overall safety population across the clinical program
• The extended safety analysis across 8 studies adetermines the safety profile of Olumiant and showed no increases in rates for AEs- SAEs- or serious infections with therapy

  Ref: Eli Lilly | Image: Eli Lilly